Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02031965 · ClinicalTrials.gov registry record · Phase 1
Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery
A Phase 1 study, sponsored by Pediatric Brain Tumor Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02031965 is a Phase 1 study that was terminated before completion, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 2 participants.
The verdict
NCT02031965, a Phase 1 study, was terminated before completion, sponsored by Pediatric Brain Tumor Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and the safety of injecting HSV1716 (a new experimental therapy) into or near the tumor resection cavity. The injection will be done at the time of surgery. HSV1716 is a virus that has a gene which has been changed or removed (mutated) in such a way that lets the virus multiply in dividing cells of the tumor and kills the tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG dexamethasone
- PROCEDURE therapeutic conventional surgery
- BIOLOGICAL oncolytic HSV-1716
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02031965
The ClinicalTrials.gov registry entry for NCT02031965 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02031965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02031965 about?
NCT02031965 is a clinical study titled "Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery". This phase I trial studies the side effects and the safety of injecting HSV1716 (a new experimental therapy) into or near the tumor resection cavity. The injection will be done at the time of surgery. HSV1716 is a virus that has a gene which has been changed or removed (mutated) in such a way that l...
What is the current status of trial NCT02031965?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2013-12. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02031965?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dexamethasone (DRUG), therapeutic conventional surgery (PROCEDURE), oncolytic HSV-1716 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02031965?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.